Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.

Santos PD, Davis A, Jandourek A, Smith A, David Friedland H.

J Chemother. 2013 Dec;25(6):341-6. doi: 10.1179/1973947813Y.0000000144. Epub 2013 Dec 6.

2.

Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.

Lipsky BA, Cannon CM, Ramani A, Jandourek A, Calmaggi A, Friedland HD, Goldstein EJ.

Diabetes Metab Res Rev. 2015 May;31(4):395-401. doi: 10.1002/dmrr.2624. Epub 2015 Jan 23.

PMID:
25417910
3.

Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.

Evans JD, Udeani G, Cole P, Friedland HD.

Postgrad Med. 2014 Sep;126(5):128-34. doi: 10.3810/pgm.2014.09.2807.

PMID:
25295657
4.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Jorgenson MR, DePestel DD, Carver PL.

Ann Pharmacother. 2011 Nov;45(11):1384-98. doi: 10.1345/aph.1Q225. Epub 2011 Oct 18. Review.

PMID:
22009993
5.

Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.

Maggiore C, Pasquale T, Cole P, Friedland HD.

Expert Rev Clin Pharmacol. 2015 Jan;8(1):141-53. doi: 10.1586/17512433.2015.986461. Epub 2014 Dec 3.

PMID:
25467425
6.

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.

Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D.

Antimicrob Agents Chemother. 2012 May;56(5):2231-6. doi: 10.1128/AAC.05738-11. Epub 2012 Feb 6.

7.

Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.

Beresford E, Biek D, Jandourek A, Mawal Y, Riccobene T, Friedland HD.

Expert Rev Clin Pharmacol. 2014 Mar;7(2):123-35. doi: 10.1586/17512433.2014.884457. Epub 2014 Feb 5. Review.

PMID:
24494793
8.
10.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

11.

The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients.

Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J.

J Infect Chemother. 2013 Feb;19(1):42-9. doi: 10.1007/s10156-012-0449-9. Epub 2012 Jul 14.

PMID:
22797874
12.

Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.

Kaye KS, Udeani G, Cole P, Friedland HD.

Hosp Pract (1995). 2015;43(3):144-9. doi: 10.1080/21548331.2015.1037228. Epub 2015 May 8.

PMID:
25956849
13.

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.

Udeani G, Evans J, Cole P, Friedland HD.

Hosp Pract (1995). 2014 Aug;42(3):109-15. doi: 10.3810/hp.2014.08.1123.

PMID:
25255412
14.

Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).

Guervil DJ, Kaye KS, Hassoun A, Cole P, Huang XY, Friedland HD.

J Chemother. 2016 Jun;28(3):180-6. doi: 10.1179/1973947815Y.0000000010.

PMID:
25817579
15.

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51. doi: 10.1093/jac/dkq254.

16.

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 2 investigators.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv53-iv65. doi: 10.1093/jac/dkq255.

17.

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.

Stryjewski ME, Jones RN, Corey GR.

Diagn Microbiol Infect Dis. 2015 Mar;81(3):183-8. doi: 10.1016/j.diagmicrobio.2014.11.016. Epub 2014 Dec 3. Review.

PMID:
25583130
18.

Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.

[No authors listed]

Med Lett Drugs Ther. 2011 Jan 24;53(1356):5-6. No abstract available.

PMID:
21252841
19.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Biek D, Critchley IA, Riccobene TA, Thye DA.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251. Review.

20.

Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).

Amara S, Adamson RT, Lew I, Huang X.

Curr Med Res Opin. 2013 Jul;29(7):869-77. doi: 10.1185/03007995.2013.803056. Epub 2013 May 23.

PMID:
23659559
Items per page

Supplemental Content

Write to the Help Desk